Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$9.21M$9.21Mderived−47.6% vs Q4 2023 Net Income-$96.55M-$96.55MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$99,676,000N/M Operating Cash Flowderived-$8,938,000N/M Free Cash Flowderived-$8,938,000N/M Margins · derivedOperating margin-1082.3%−1059.2 pt vs Q4 2023
Net margin-1048.3%−1039.9 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 27, 2025 · 58 d after period end